Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

NCT02433236 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study withdrawn prior to enrollment of first subject

Conditions

IGA Nephropathy

Interventions

DRUG: Fostamatinib Disodium tablet 100 mg
DRUG: Fostamatinib Disodium tablet 150 mg

Sponsor

Rigel Pharmaceuticals